Companies › Hudson Biotech
7 active drug programs in 8 registered trials: 7 Phase 2, 1 Phase 1; Metabolic and endocrine, Other, Immunology, Gastroenterology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Afamelanotide Melanocortin receptor 1 agonist | MC1R | Phase 2 | NonSegmental Vitiligo | Feb 2027 |
| GHK-Cu Gel Copper(II)-peptide complex with tissue repair activity | – | Phase 2 | Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds) | Feb 2027 |
| MOTS-c (MDP) Mitochondrial-derived peptide | – | Phase 2 | Prediabetes | Feb 2027 |
| Pentadecapeptide BPC 157 Cytoprotective peptide; mechanisms not fully characterized but proposed to involve angioge | – | Phase 2 | Hamstring Muscle Strain | Feb 2027 |
| Tesamorelin Growth hormone-releasing hormone receptor agonist | GHRHR | Phase 2 | Metabolic Associated Steatotic Liver Disease; HIV-1-infection | Feb 2027 |
| Retatrutide (LY3437943) Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist | GCGR, GLP1R, GIPR | Phase 2 | Obesity | Mar 2027 |
| TB-500 Thymosin beta 4 17-23 fragment | TMSB4X | Phase 1 | Atherosclerotic Cardiovascular Diseases | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07437560 | Afamelanotide | Phase 2 | NonSegmental Vitiligo | Immunology | Feb 2027 |
| NCT07505745 | MOTS-c (MDP) | Phase 2 | Prediabetes | Metabolic and endocrine | Feb 2027 |
| NCT07437547 | Pentadecapeptide BPC 157 | Phase 2 | Hamstring Muscle Strain | Other | Feb 2027 |
| NCT07481734 | Tesamorelin | Phase 2 | Metabolic Associated Steatotic Liver Disease | Gastroenterology | Feb 2027 |
| NCT07487363 | TB-500 | Phase 1 | Atherosclerotic Cardiovascular Diseases | Cardiovascular | Feb 2027 |
| NCT07437586 | GHK-Cu Gel | Phase 2 | Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds) | Other | Feb 2027 |
| NCT07467447 | Retatrutide (LY3437943) | Phase 2 | Obesity | Metabolic and endocrine | Mar 2027 |
| NCT06554717 | Tesamorelin | Phase 2 | HIV-1-infection | Infectious disease | Jun 2028 |
Eli Lilly Novo Nordisk Roche AstraZeneca Hanmi Pharmaceutical Company Hangzhou Sciwind Biosciences Boehringer Ingelheim Altimmune Amgen Regeneron Pharmaceuticals
Fujian Shengdi Pharmaceutical Shanghai Minwei Biotechnology Beijing QL Biopharmaceutical Daewoong Pharmaceutical Shanghai Argo Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.